Piero Parchi

This study examines gut microbiota alterations in Down syndrome and their link to Alzheimer's disease biomarkers and cognitive decline.

This study detects alpha-synuclein seeding activity in tear fluid from Parkinson's disease patients using aSynSAA, showing higher activity in PD compared to controls and prion disease.

This study identifies genetic variants associated with clinical duration in sporadic CJD but finds no significant SNPs for age at onset.

The paper shows that in prion diseases, microglia engulf viable neurons during late preclinical stages, independent of the CD11b pathway, and this occurs across multiple brain regions and sCJD subtypes.

The paper develops a targeted mass spectrometry method to quantify prion protein in CSF, confirming that reduced PrP levels in prion disease are due to the disease process, not ELISA artifacts.

This paper quantifies the challenges of designing preventive clinical trials for genetic prion disease due to high variability in age of onset, suggesting the need for biomarker-based trials.

This study evaluates ELISA-based quantification of PrP in CSF as a biomarker for PrP-reducing therapeutics, showing its reliability and CNS origin.